Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAN-101-03 Phase 2a in Celiac Disease
2023-507240-37-00Phase 2Completed
- Sponsor
- Anokion
- Start
- Apr 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Modified Peptides → Peptides, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing KAN-101 with Placebo (2 arms). Started Apr 2024; status: completed.
02
Drugs
KAN-101
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2023-507240-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507240-37-00.